Q-omics provides the consensus-scored DUSP7 profile across patient tissues and cancer cell-line models. DUSP7 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, DUSP7 is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, DUSP7 RNA expression shows 20,451 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight MESO, COAD, and ACC as cancer lineages where DUSP7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DUSP7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DUSP7 survival associations across molecular data types. DUSP7 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (7) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DUSP7 RNA expression–survival associations across cancer types. High DUSP7 expression shows unfavorable associations in MESO, KIRP, ACC, LIHC, PAAD and LAML. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for DUSP7 RNA expression.
This table summarizes DUSP7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for DUSP7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DUSP7 shows lower tumor expression in BRCA and higher tumor expression in COAD, KIRC, HNSC, LIHC and READ. The COAD box plot shows higher DUSP7 RNA expression in tumor versus normal tissue (log2 FC = +0.886, t-test p < 0.001).
This table shows molecular features associated with DUSP7 in patient tissues and cancer cell lines. In patient samples, DUSP7 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, DUSP7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
